Access to anti-retroviral drugs, female in Niger

Niger: Access to anti-retroviral drugs, female was 79.0% in 2024. ◆ Volatile

Latest (2024)
79.0%
Change on year
down 4.8%
World rank
59th
of 141 countries
All-time high
85.0%
in 2020
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Niger, 2000–2024

0204060802000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 2 %2006: 6 %2007: 8 %2008: 10 %2009: 24 %2010: 28 %2011: 36 %2012: 42 %2013: 50 %2014: 45 %2015: 52 %2016: 60 %2017: 72 %2018: 79 %2019: 81 %2020: 85 %2021: 85 %2022: 84 %2023: 83 %2024: 79 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, female in Niger stood at 79.0%.

The figure is down 4.8% on the previous year and up 75.6% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Niger peaked at 85.0% in 2020 and was at its lowest, 0.0%, in 2000.

That places Niger 59th out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Niger, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Niger, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 2.0%
2006 6.0% +200.0%
2007 8.0% +33.3%
2008 10.0% +25.0%
2009 24.0% +140.0%
2010 28.0% +16.7%
2011 36.0% +28.6%
2012 42.0% +16.7%
2013 50.0% +19.0%
2014 45.0% -10.0%
2015 52.0% +15.6%
2016 60.0% +15.4%
2017 72.0% +20.0%
2018 79.0% +9.7%
2019 81.0% +2.5%
2020 85.0% +4.9%
2021 85.0% +0.0%
2022 84.0% -1.2%
2023 83.0% -1.2%
2024 79.0% -4.8%

Averages by decade

DecadeAverage LowestHighest Years
2000s 5.0% 0.0% 24.0% 10
2010s 54.5% 28.0% 81.0% 10
2020s 83.2% 79.0% 85.0% 5

Countries ranked near Niger

  1. 56 Portugal 82.0% compare
  2. 57 Bhutan 80.0% compare
  3. 57 New Zealand 80.0% compare
  4. 60 Congo, Democratic Republic of the 78.0% compare
  5. 60 Cuba 78.0% compare
  6. 60 Myanmar 78.0% compare

See the full ranking of 160 places →

More gender data for Niger

All data for Niger →

Frequently asked questions

What is access to anti-retroviral drugs, female in Niger?
Access to anti-retroviral drugs, female in Niger was 79.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Niger?
The highest recorded value was 85.0% in 2020.
What is the lowest access to anti-retroviral drugs, female recorded in Niger?
The lowest recorded value was 0.0% in 2000.
How does Niger rank for access to anti-retroviral drugs, female?
Niger ranks 59th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Niger?
Over the last ten years it is up 75.6%. The long-run trend across the full record is volatile.
Where does this Niger data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Niger. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/niger/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/niger/">Access to anti-retroviral drugs, female in Niger</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.